develop reduc pt account financ dilut
focu small molecul
address
dysfunct protein process compani recent report juli
first patient dose global phase studi
cystic fibrosi cf patient assess cystic fibrosi transmembran
rang find identifi util
compani third gener corrector
compani first gener potenti without inclus
compani first gener amplifi phase trial
assess includ safeti sweat chlorid concentr chang
doublet triplet cftr modul combin evalu
homozyg heterozyg cf patient compani
anticip phase data cf patient encourag
note manag explor global partnership opportun
best leverag strength platform asset evalu
posit cftr modul program within landscap
cf therapeut develop reduc price target
driven account financ dilut rather
lack confid compani approach reiter
buy rate
definit distribut analyst rate analyst certif disclosur pleas refer page report
thought strategi context phase combin observ march phase result cf patient
interpret context deliveri vertex buy rate tripl data demonstr
improv lack viabl near-term competitor cftr modul space believ
combin pti compound could gener improv provid viabl competitor
vertex identif molecul could serv possibl add-on modul vari phase
combin either follow treatment reach improv continu believ
due lack competit cf landscap ex-u desir treatment option fuel possibl ema traction
pti platform continu warrant explor view manag highlight phase doublet triplet
combin provid insight efficaci contribut maintain possibl development
path gain traction could ultim includ pursuit second-lin therapi treat sever affect cf patient
experienc signific improv vertex regimen treatment view attract approach
sever reason current competitor cohort would welcom cf commun
may even welcom eu countri face negoti difficulti vertex drug addit path
compani pursu refin trial protocol exclud patient colon cepacia abscessu also
extend look-back period day furthermor per manag follow trial focu consist dose
regimen tripl therapi mg respect trial treatment period day
homozyg heterozyg patient note perhap best option ultim could
pursuit scenario
number second quarter compani report research develop expens
gener administr expens second quarter compani report net loss
second quarter june compani report cash equival
valuat risk reduc price target driven account financ dilut rather
lack confid compani approach reiter buy rate price target base
probability-adjust npv cf discount rate growth rate line expect discount
growth paramet development-stag compani cash risk invest thesi target price includ
failur clinic studi failur secur regulatori approv smaller anticip commerci opportun
due market size competit and/or price
revenu
revenu
revenu
revenu
modif seri
accru dividend prefer stock
net loss attribut common
except per share valu
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori proteostasi inc pti-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl august
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein matthew caufield li wang watsek alicia yin ph certifi view express
report accur reflect person view subject secur issuer discuss part
compens directli indirectli relat specif recommend view express research
report neither member household offic director advisori board member
none research analyst research analyst household financi interest secur proteostasi
therapeut inc inc includ without limit option right warrant futur long short
juli neither firm affili benefici class common equiti secur
proteostasi inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm affili receiv compens proteostasi therapeut inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
 wainwright co llc manag co-manag public offer secur proteostasi inc
past month
firm make market proteostasi inc inc date
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
